Abstract 1978
Background
Triple-negative breast cancer (TNBC) patients who achieve a pathologic complete response (pCR) after Neoadjuvant chemotherapy (NAC) have better prognoses. This study intended to develop an intuitive nomogram based on simple blood indexes to predict the pCR of standard NAC in TNBC patients with an ultimate aim to tailor more beneficial treatments and improve outcomes.
Methods
A total of 80 TNBC patients who received standard NAC, 4 cycles of anthracycline (epirubicin or adriamycin) and cyclophosphamide followed by 4 cycles of taxane, and subsequent surgery in Zhejiang Cancer Hospital between January 2016 and December 2018 were retrospected and their pre-treatment clinical features and several simple blood indexes were collected. The optimal cutoff values of blood indexes were determined by Youden index using the receiver operating characteristic (ROC) curve analysis. The forward stepwise logistic regression (likelihood ratio) analysis was applied to identify predictive factors for pCR of NAC. Then a nomogram was developed according to the logistic model. The calibration of the nomogram was carried out by internal validation with the bootstrap resampling approach and displayed using a calibration curve. The goodness of fit for the model was checked by a Hosmer-Lemeshow test. The discrimination of the nomogram was graphically shown by the ROC curve and quantified by the area under the curve (AUC).
Results
The pCR was achieved in 39 (48.8%) patients after NAC. Multivariate logistic regression analysis identified four independent indicators: clinical tumor stage, lymphocyte monocyte ratio, fibrinogen and D-dimer. The nomogram established based on those factors showed its discrimination with an AUC of 0.803 (95% CI 0.706-0.899) and a bias-corrected AUC of 0.771. The calibration curve and Hosmer-Lemeshow test showed the prediction of the nomogram was a good fit with actual observation.
Conclusions
Based on four simple, easily accessible, inexpensive and objective factors, the nomogram proposed in the present study exhibited a sufficient ability of discrimination for predicting pCR of NAC in TNBC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1849 - Effect of thioredoxin 1 quantity detection to complement the mammography in breast cancer diagnosis
Presenter: Younju Lee
Session: Poster Display session 2
Resources:
Abstract
2221 - Identification of ultralow risk breast cancer patients (probable overdiagnosis)
Presenter: Salvador Gamez Casado
Session: Poster Display session 2
Resources:
Abstract
5291 - Prevalence of Vitamin D3 deficiency among women with early breast cancer receiving chemotherapy in an oncology dayward.
Presenter: Warner Finstad
Session: Poster Display session 2
Resources:
Abstract
4247 - Changes in ER pathway activity score during neoadjuvant letrozole to assess therapy response and predict disease free survival (DFS) in ER positive breast cancer patients
Presenter: Arran Turnbull
Session: Poster Display session 2
Resources:
Abstract
568 - Second primary malignancies in patients with breast cancer.
Presenter: Carlos Erasun Lecuona
Session: Poster Display session 2
Resources:
Abstract
1428 - Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab (TP) with either palbociclib + letrozole (Pal+L) or paclitaxel (Pac) for elderly patients with estrogen receptor & HER2 positive (ER+/HER2+) Breast Cancer (BC) (International Breast Cancer Study Group IBCSG 55-17, TOUCH)
Presenter: Laura Biganzoli
Session: Poster Display session 2
Resources:
Abstract
1479 - Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): an open label randomized phase 2 trial
Presenter: Heather McArthur
Session: Poster Display session 2
Resources:
Abstract
1481 - A randomized phase 2 study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy
Presenter: Heather McArthur
Session: Poster Display session 2
Resources:
Abstract
4334 - ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer.
Presenter: Michail Ignatiadis
Session: Poster Display session 2
Resources:
Abstract
2107 - Role of Individualized Intervention(s) on Quality of Life (QOL) and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women with Early-Stage Breast Cancer (BC): MyChoice Study
Presenter: Shahid Ahmed
Session: Poster Display session 2
Resources:
Abstract